Direct from our state-of-the-art synthesis facility in Hangzhou, China. Rigorously verified via RP-HPLC, High-Resolution MS, and lot-specific Certificates of Analysis.
Bridging the analytical chasm between milligram laboratory proof-of-concept and commercial multi-ton peptide Active Pharmaceutical Ingredient (API) requirements.
Historically, endogenous and biologically derived "natural peptides"—such as vasopressin, oxytocin, ACTH fragments, and native incretins—were extracted from biological tissues with minimal yields, high inter-batch heterogeneity, and severe immunogenic risks. Today, modern pharmaceutical and cosmeceutical enterprises demand bio-identical fidelity produced through synthetic chemistry. This transition necessitates absolute sequence control, stereochemical precision, and scalable purification methods that eradicate host-cell contaminants, biological endotoxins, and hazardous residual solvents.
Procurement executives and Chemistry, Manufacturing, and Controls (CMC) leads in North America, the European Union, and across Asia face steep hurdles when selecting manufacturing partners. The most critical operational barriers include sequence truncation, beta-elimination during deprotection, epimerization of sterically hindered amino acid residues (such as C-terminal Cys or His), and residual trifluoroacetic acid (TFA) exchange. Hangzhou Thinheal Pharma-Tech Co., Ltd., founded in 2019, addresses these systemic friction points through a comprehensive synthesis, downstream purification, and regulatory-support infrastructure.
Implementation of modern coupling reagents like OxymaPure/DIC alongside low-temperature fragment condensation prevents D-enantiomer racemization during extensive peptide elongations, ensuring bio-identical therapeutic activity.
Our multi-ton industrial reactor lines utilize automated solvent-recovery systems and optimized solid-support loading, lowering the raw cost per gram of API while safeguarding batch reproducibility across 50kg+ validation lots.
Seamless conversion from raw trifluoroacetate (TFA) salts to pharmaceutical-grade acetate, hydrochloride, or pamoate complexes, achieving residual TFA levels beneath 0.1% to guarantee safety in parenteral formulations.
Combining Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and emerging chemo-enzymatic peptide ligation.
By integrating thermal and high-flow acoustic cavitation during repetitive deprotection and coupling cycles, Thinheal mitigates beta-sheet secondary aggregation in difficult, lengthy sequences like GLP-1 and GLP-2 dual agonists (30–45 amino acids).
Replacing traditional N,N-dimethylformamide (DMF) and N-methyl-2-pyrrolidone (NMP) with bio-based green solvents like 2-MeTHF and Cyrene. Our processes reduce the E-factor (environmental impact factor) by over 62% per kilogram of completed bulk product.
Implementing engineered peptide ligases (Peptiligase / Butelase) for convergent block coupling. This methodology bypasses aggressive chemical reagents, significantly boosting overall yields for lipidated metabolic peptide therapeutics.
For peptides exceeding 30 amino acids, linear synthesis frequently experiences an exponential decline in chromatographic resolution due to the accumulation of deletion sequences that closely match the molecular weight and hydrophobicity of the target product. At Thinheal, our technical team deploys a hybrid convergent strategy: short, protected peptide fragments (typically 5 to 12 residues) are synthesized with high throughput via SPPS on chlorotrityl resins, purified, and subsequently coupled in solution phase. This method simplifies chromatography, achieves purities >99.5%, and shortens lead times for multi-kilogram campaign orders.
Representative wholesale parameters for active commercial projects. Final contract pricing varies based on lot volume, required counter-ion, and analytical validation tiers.
| Peptide Name | CAS Number | Primary Indication / Mechanism | Standard Purity | Counter-Ion | Standard Batch Scale | Procurement Tier |
|---|---|---|---|---|---|---|
| Semax | 80714-61-0 | CNS Neuroprotective / ACTH Analogue | ≥98.5% | Acetate / Lyophilized | 500g – 20kg | Commercial Stock |
| Selank | 129954-34-3 | Tuftsin Analogue / Anxiolytic Solution | ≥99.0% | Acetate | 1kg – 10kg | Commercial Stock |
| Mazdutide | 2259884-03-0 | Dual GLP-1 / Glucagon Receptor Agonist | ≥98.0% | Acetate / TFA-free | 100g – 5kg | Custom CDMO |
| Vasopressin (ADH) | 50-57-7 | V1a / V2 Receptor Agonist / Antidiuretic | ≥98.5% | Acetate | 500g – 50kg | Commercial Stock |
| Tirzepatide | 2023788-19-2 | GIP / GLP-1 Dual Incretin Agonist | ≥99.0% | Acetate / Free base | 1kg – 100kg | High Capacity |
| Setmelanotide | 920014-72-8 | MC4 Receptor Agonist / Obesity Treatment | ≥98.0% | Acetate | 100g – 2kg | Custom CDMO |
| Eptifibatide | 188627-80-7 | GPIIb/IIIa Platelet Antagonist | ≥99.2% | Acetate / Sterile bulk | 1kg – 25kg | Commercial Stock |
| Thymosin β4 (TB500) | 77591-33-4 | Actin-Sequestering Regenerative Peptide | ≥98.0% | Acetate | 500g – 20kg | Commercial Stock |
| Triptorelin | 57773-63-4 | GnRH Receptor Agonist / Oncology | ≥99.0% | Pamoate / Acetate | 500g – 15kg | Commercial Stock |
| Bremelanotide (PT141) | 189691-06-3 | Melanocortin Receptor Agonist | ≥98.5% | Acetate | 500g – 10kg | Commercial Stock |
* Custom formulations, deuterated tags, cyclic disulfide bridges, and regulatory dossier support (US FDA DMF / EU ASMF) available upon qualification.
Ensuring analytical transparency and direct export compliance for buyers across Europe, the Americas, and the Asia-Pacific region.
Every commercial batch is produced within classified cleanrooms following strict ICH Q7 active substance parameters. Methods are validated in direct accordance with USP, EP, and ChP guidelines.
Deliverables feature comprehensive analytical packages: high-resolution Orbitrap mass spectrometry, 2D NMR conformation checks, chiral amino acid enantiomer analysis, Karl Fischer water testing, and bioburden endotoxin assays.
Specialized temperature-regulated transport systems (-20°C / -80°C validated vacuum insulation with real-time data loggers) ensure stability during transit to the US, Western Europe, UAE, and East Asia.
In-depth insights into process validation, regulatory compliance, testing thresholds, and custom CDMO services.
Explore our additional portfolio of synthetic GnRH agonists, antidiuretic controls, dual incretins, and melanocortin receptor solutions.
Thin